We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction to Protein Structure and Function
-
1. Nature’s strategies in the regulation of enzyme activity by modifiers
- Prof. Antonio Baici
- Creation of Protein Variability by Manipulation of Genes
-
3. Perspectives on biological catalysis
- Prof. Stephen Benkovic
-
4. Fundamentals and principles for engineering proteolytic activity
- Prof. Charles Craik
- Metabolic Diseases Caused by Genetic Mutation
-
5. Modifications of pyruvate handling in health and disease
- Prof. Mary Sugden
-
6. Mitochondrial fatty acid oxidation deficiencies
- Prof. Niels Gregersen
-
7. Inborn errors of ketone body metabolism
- Prof. Toshiyuki Fukao
-
8. Cathepsin K in bone and joint diseases
- Prof. Dieter Bromme
-
9. Fabry disease: alfa-galactosidase A deficiency and enzyme replacement therapy
- Prof. David Warnock
-
10. Acid beta-glucosidase/glucocerebrosidase (GCase)
- Prof. Gregory Grabowski
-
11. GM2 gangliosidosis future treatments 1
- Prof. Brian Mark
-
12. GM2 gangliosidosis future treatments 2
- Prof. Brian Mark
-
13. The neuronal ceroid lipofuscinoses
- Prof. Sandra Hofmann
- Disorders of Blood Coagulation
-
14. Advances in fibrinolysis
- Dr. Paul Kim
-
16. Structure of thrombin, a Janus-headed proteinase
- Prof. Wolfram Bode
-
18. Fibrinogen and factor XIII
- Prof. John Weisel
-
19. Factor VIII and haemophilia A
- Dr. Geoffrey Kemball-Cook
-
20. Factor IX
- Prof. Bruce Furie
-
21. The biology and pathobiology of von Willebrand factor
- Prof. David Lillicrap
-
22. Thrombotic thrombocytopenic purpura
- Prof. J. Evan Sadler
-
23. Fibrinolysis
- Prof. Edward Tuddenham
- Other Molecular and Metabolic Disorders
-
24. Glucose-6-phosphate dehydrogenase deficiency
- Dr. Jane Leopold
-
25. Cytochrome b5 reductase deficiency and hereditary methemoglobinemia
- Dr. Scott Reading
-
26. Sickle cell disease
- Prof. Martin H. Steinberg
-
27. Pyruvate kinase deficiency
- Prof. Alberto Zanella
-
28. Heritable disorders of collagen
- Dr. Heather Yeowell
-
29. Duchenne muscular dystrophy
- Prof. Jeff Chamberlain
- Archived Lectures *These may not cover the latest advances in the field
-
30. Protein crystallography
- Prof. Michael James
-
31. Regulation of blood coagulation by the serpin, antithrombin
- Prof. Steve Olson
-
32. Rhodopsin and retinitis pigmentosa
- Dr. Shalesh Kaushal
-
33. The physiology and pathology of coagulation factor XI
- Dr. David Gailani
-
34. Cytochrome b5 reductase deficiency and hereditary methemoglobinemia
- Prof. Josef Prchal
-
35. Metachromatic leukodystrophy
- Prof. Volkmar Gieselmann
-
36. Serpins and serpinopathies
- Dr. James Whisstock
-
38. Pleiotropic and epistatic genes in sickle cell anaemia
- Prof. Ronald Nagel
-
39. Genetic disorders of carbonic anhydrases II and IV
- Prof. William Sly
-
40. GM2 gangliosidoses
- Prof. Don Mahuran
-
41. Kinetic analysis of protein activity
- Prof. Antonio Baici
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture topics
- Balance in blood
- Fibrinolysis and factor XIII
- Formation and lysis of blood clots
- Plasminogen modules
- Serpins (PAI-1 and alpha-2AP)
- Inhibition by serpins PAI-1 and alpha-2AP
- Fibrinogen structure - 6 chains
- Fibrinogen structure
- Fibrin monomer formation and polymerization
- Fibrin network (plasma clot)
- Fibrin the assembler
- Regulation - two key elements
- Formation and lysis of fibrin
- TAFIa modulation of fibrinolysis
- Plasma fibrinolysis (1)
- Fibrinolysis in the plasma
- Clot lysis assay
- Fibrin lysis assay
- Neutralize TAFI and serpins
- Model thrombi
- Chandler model thrombus
- In situ zymography
- Visualizing both fibrin formation and lysis
- PMN-associated uPA
- Endogenous lysis in Chandler model thrombi
- Lysis of leucocyte-rich PRP model thrombi
- PMN and lysis
- PMN + plasma generate uPA
- PMN - two opposing roles
- Plasma fibrinolysis (2)
- Euglobulin
- Activity on fibrin-agarose plate
- What can the plasma tell us?
- Genetic deficiency syndromes
- Summary
- Acknowledgements
Topics Covered
- Biochemistry and physiology of fibrinolysis
- The balance of fibrinolysis in blood, activators and inhibitors
- Assays of fibrinolysis, clot lysis, model thrombi under flow, in situ zymography and euglobulin lysis
- Genetic deficiency syndromes
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tuddenham, E. (2015, September 30). Fibrinolysis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/AZIY7034.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Edward Tuddenham has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cell Biology
Transcript
Please wait while the transcript is being prepared...
0:04
In this lecture on Fibrinolysis,
we will cover the role of Fibrinolysis as an integral part of haemostasis,
the biochemistry of the interactions which make up the process,
where it happens with insights gained from
experiments using plasma or whole blood and what
we can practically measure and what it tells
us in relation to bleeding and thrombosis in the clinic.
Putting it all together,
you should be able to conceive of Fibrinolysis as
an active process occurring at the same time as and subsequent to haemostasis.
0:50
In normal blood, a balance exists between
a process of clot formation and its dissolution of Fibrinolysis.
An imbalance in either direction can cause,
on the one hand,
thrombosis if there's inadequate clotlysis or bleeding if clotlysis is overactive.
1:15
This diagram summarizes the actors in the dynamic process of clot formation and clot
dissolution by Fibrinolysis together with
the specific activators and
the specific inhibitors which regulate the process and keep it in balance.
Shown centrally, in red,
is Thrombin the terminal enzyme of the coagulation cascade.
Thrombin is multi-functional.
Its roles shown here,
which are a subset of its nine roles,
are firstly to convert
soluble Fibrinogen to fibrin monomers which spontaneously polymerize.
Thrombin also activates plasma factor XIII to factor XIIIa, a transglutaminase.
Factor XIIIa cross links the fibrin meshwork giving its stability.
As soon as fibrin has formed,
it begins to absorb plasminogen and tissue plasminogen activator,
thereby accelerating the generation of the active enzyme plasmin,
which in turn starts to degrade
cross-linked fibrin yielding fibrin degradation products, FDPs.
This part of the process is tightly regulated by serine proteinase inhibitors or serpins,
shown as purple lozenges,
one being specific for each active enzyme.
PAI-1 is the inhibitor of TPA,
alpha 2 anti-plasmin of plasmin,
and anti-Thrombin of Thrombin.
Another action of Thrombin in the presence of thrombomodulin or TM,
an endothelial surface receptor,
is to convert TAFI or Thrombin activatable Fibrinolysis inhibitor,
to an active form, a carboxypeptidase,
which removes specific lysine residues from fibrin,
rendering it unable to bind plasminogen and TPA and thus
switching off the process of active plasmin generation.